Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data

2021 ◽  
Author(s):  
Ashton A. Connor ◽  
Steven Gallinger
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Data ◽  
Cancer Evolution

scholarly journals Pancreatic Cancers: A Review of Studies from Pakistan and Comparison with Global Trends

2021 ◽  
Vol 11 (2) ◽  
pp. 120-127
Author(s):  
Saleema Mehboob Ali ◽  
Yumna Adnan ◽  
S. M. Adnan Ali
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Data ◽  
Association Studies ◽  
Epidemiological Data ◽  
Review Article ◽  
Diagnostic Tools ◽  
Global Trends ◽  
Pancreatic Cancers ◽  
The World ◽  
Prediction Of Prognosis

The objective of this review article is to discuss clinical data from studies on Pakistani pancreatic cancer population and its comparison with international data. This review article will allow researchers to identify gaps in the data and hence to design further research in order to address these gaps accordingly. Search was carried out via Google Scholar, PubMed and PakMediNet search engines using keywords “Pancreatic cancers”, “Pancreatic adenocarcinoma” and “Pakistan”. Pancreatic cancers are one of the most lethal cancers globally. Statistics show that 97.8% of cases of pancreatic cancers in Pakistan have led to mortality. For various cancers around the world, epidemiological data has been used for development of diagnostic tools and therapies. Despite the alarming situation of pancreatic cancers in Pakistan, only limited work has been done in this area. Majority of the studies are based exclusively on reporting of clinical data. Pakistan has not been able to even gather sufficient data to proceed research based on association of molecular aspects of tumor with clinical characteristics. On the contrary, researchers, scientists and clinicians from other parts of the world are already working on association studies, prediction of prognosis, treatment selection and improving the survival of their population. It is an immense need of the situation that molecular based studies are carried out on Pakistani pancreatic cancer population so that diagnosis, prognosis, treatment and survival of these patients can be made better.

Carbon ion radiotherapy in pancreatic cancer: A review of clinical data

2020 ◽  
Vol 147 ◽  
pp. 145-150
Author(s):  
Jakob Liermann ◽  
Makoto Shinoto ◽  
Mustafa Syed ◽  
Jürgen Debus ◽  
Klaus Herfarth ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Data ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ion

JASPAC 06: Observational study of FOLFIRINOX therapy for unresectable and recurrent pancreatic cancer—Preliminary report on serious adverse events.

2016 ◽  
Vol 34 (4_suppl) ◽  
pp. 407-407
Author(s):  
Masato Ozaka ◽  
Akiko Todaka ◽  
Keita Mori ◽  
Narikazu Boku ◽  
Nobumasa Mizuno ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Adverse Events ◽  
Observational Study ◽  
Clinical Data ◽  
Preliminary Report ◽  
Japanese Patients ◽  
Inclusion Criteria ◽  
Serious Adverse Events ◽  
Recurrent Pancreatic Cancer ◽  
Ecog Ps

407 Background: In Japan, indication of FOLFIRINOX for unresectable and recurrent pancreatic cancer was approved in 2013. Because clinical data of FOLFIRINOX in Japanese patients based on only one exploratory trial is limited, this observational study was conducted to survey practical use of FOLFIRINOX and to evaluate incidences of adverse events in Japanese patients. Methods: The subjects were patients with unresectable or recurrent pancreatic cancer who received FOLFIRINOX therapy during one year from Dec. 20, 2013 (approval date of this study). All the subjects were registered and their clinical data were sent to the data center. In this preliminary report, we analyzed patients’ characteristics related to serious adverse event (SAE). This study was approved by the IRB in each institution. Results: Four hundred patients (pts) were registered from 27 institutions in Japan. Median age was 63 years (range 27-80). Sixty-four percent (n = 254) had no prior treatment and 254 pts (60%) had distant metastatic lesions. The UGT1A1 genotype was wild-type in 56.8% of the subjects, heterozygous (*1/*6, *1/*28) in 39.3%, and homozygous (*6/*6, *6/*28, *28/*28) in 3.9%. One hundred forty-one SAEs in 115 pts (28.8％) were reported until Aug. 10, 2015. Most common SAEs were febrile neutropenia (n = 26), neutrophil count decreased (n = 26), anorexia (n = 21) and biliary tract infection (n = 18). Of these 141 events, five events were results in death. The proportion of patients who met the inclusion criteria (as follows: ECOG PS of 0 or 1; age 20-75 years; adequate hematological, liver and renal functions) used in the phase II trial of FOLFIRINOX for Japanese patients was significantly lower in the subjects with SAEs than those without SAE (60.5% vs. 72.4%, p = 0.023). Four of the 5 pts who resulted in death did not fulfill the inclusion criteria; C-reactive protein in 4, platelet count in 1 and hemoglobin in 1. Conclusions: This is a first report to evaluate the safety profile of FOLFIRINOX in Japanese pancreatic cancer patients. These data highlight the importance of patient selection for FOLFIRINOX. The final safety and efficacy results of this study will be reported at the coming meeting. Clinical trial information: UMIN000014658.

scholarly journals A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns

Nature ◽  
2016 ◽  
Vol 538 (7625) ◽  
pp. 378-382 ◽  
Author(s):  
Faiyaz Notta ◽  
Michelle Chan-Seng-Yue ◽  
Mathieu Lemire ◽  
Yilong Li ◽  
Gavin W. Wilson ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Genomic Rearrangement ◽  
Cancer Evolution

scholarly journals PI3Kα targeting, nipping pancreatic cancer evolution in the bud

2021 ◽  
Author(s):  
Glancis Luzeena Raja Arul ◽  
Martin E Fernandez‐Zapico
Keyword(s):  
Pancreatic Cancer ◽  
Cancer Evolution

Epithelial-mesenchymal transition (EMT) in resected pancreatic cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 4094-4094
Author(s):  
V. D. Yosuico ◽  
T. Khoury ◽  
J. Yu ◽  
A. Pande ◽  
M. Javle
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Data ◽  
Histological Grade ◽  
Hazard Model ◽  
Cox Proportional Hazard Model ◽  
Proportional Hazard ◽  
Proportional Hazard Model ◽  
Chi Square ◽  
Cox Proportional Hazard ◽  
E Cadherin

4094 Background: EMT plays an important role in tumor invasion and metastases; its detection may have prognostic significance. We examined expression of EMT related proteins in resected pancreatic cancers and correlated results with clinical outcome. Methods: Clinical data/surgical specimens from 34 consecutive pancreatic cancer patients (pts) who underwent pancreatectomy from 1996–2002 were included. Immunohistochemical staining for vimentin (Vim 3B4), E-cadherin (36B5), MIB1 and cytokeratin (CK-AE1/AE3) was performed on formalin fixed paraffin embedded tissues. Percentages of stained cells (cytoplasmic for vimentin and CK, nuclear for MIB1 and membranous for E-cadherin) were recorded. The results were correlated with clinicopathological parameters and survival. Survival analysis (log-rank test, Cox-proportional hazard model), categorical data analysis (Pearson’s chi-square, logistic regression) and Kendall’s tau were performed at the significance level of 0.05. Results: Clinical data/specimens from 34 pts were included: 13 males, median age 66 (range 38–84); SEER stage 1 (2 pts), 2 (27 pts), 3 (5 pts); histological grade 1 (4), 2 (13), 3 (16), 4 (1). Median survival was 15 months (95% CI: 11–24 months). Sixteen pts had adjuvant chemoradiotherapy, 4 pts had chemotherapy, 1 pt had radiation. IHC Results: vimentin (11.8%), MIB1 (100%), E-cadherin (91%) and CK (100%). There was a significant negative association between vimentin and E-cadherin expression (Kendall’s tau = −0.47, p = 0.0024). Vimentin expression correlated with histological grade (exact chi-square p = 0.0247). No associations were found between these proteins and SEER stage, age, treatment or smoking. Univariate analysis revealed histological grade 50% (p = 0.0039) and MIB1 expression >10% (p = 0.0224) were related to better survival. Multivariate analysis using Cox-proportional hazard model revealed the following significant variables: histological grade (hazard ratio (HR) = 11.8, p = 0.0001), age (HR = 1.1, p = 0.0053), MIB1 (HR = 0.9, p = 0.0003) and adjuvant chemotherapy (HR = 0.2, p = 0.0288). Conclusion: Decreased E-cadherin expression (<50% expression) was associated with poorer survival; E-cadherin expression had an inverse correlation with vimentin. Acknowledgement: Supported by OSI Pharmaceuticals. [Table: see text]

Analysis of preclinical and clinical data on the role of hyperthermia with gemcitabine and carboplatin on pancreatic adenocarcinoma

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 14123-14123
Author(s):  
S. O. Peters ◽  
A. S. Stoltz ◽  
A. Bakshandeh ◽  
M. Vollmert ◽  
T. Wagner
Keyword(s):  
Cell Cycle ◽  
Pancreatic Cancer ◽  
Overall Survival ◽  
Pancreatic Adenocarcinoma ◽  
Clinical Data ◽  
Whole Body ◽  
High Morbidity ◽  
Human Pancreas ◽  
Preclinical Data

14123 Background: Preclinical data show synergism of whole body hyperthermia (HT) of 41.8°C with gemcitabine (G) and carboplatin (CP) in lung head and neck tumor cell lines. Advanced pancreatic adenocarcinoma is an aggressive disease and is associated with high morbidity and a median survival of 8 to 12 months. The role of whole body HT with G and CP in the treatment of pancreatic cancer is unknown. Methods: We first show preclinical data to study the effects of combining HT of 37°, 39°, 41.8 and 43°C for 1 h with G and CP on the human pancreas carcinoma cell line DAN-G. We assessed proliferation ratios using crystal-violett assays and cell cycles by flow cytometry. We secondly analyzed the clinical outcome of 13 pts that received whole body HT of 41.8°C with G and CP for advanced pancreatic cancer on a compassionate-use basis at our institution between 2000 to 2004 was assessed for toxicity, response and overall survival. Results: Preclinical studies showed no effects of HT of 37, 39 and 41.8°C on DAN-G cell proliferation and cell cycle behaviour when used alone without cytostatic drugs. At 43°C cells decompose (in all experiments). Additional G and/or CP at concentrations of IC50 to HT of 37, 39, 41, 8°C did not alter the effects of the drugs alone. Cell cycle anaylsis showed that an increment of temperatures did not effect cycle phases. Analysis of the clinical data of patients whole body HT with G and CP showed partial remissions in 3 pts (23%) and no change situations in 5 pts (38%). Of 13 pts received only 2 cycles because of disease progression (n = 5) or because they refused to further treatment due to minor toxicities. 4 pts received all 4 therapy cycles initially planned. Overall survival was 11.4 months, one year survival for all patients was 38%. Generally the treatment was well tolerated. Grade 3–4 toxicities were thrombocytopenia in one patient and therapy induced anemia and neutropenia in another patient occurring after the forth cycle of treatment. Conclusions: Preclinical and clinical data show that HT plus G and CP is of no benefit in the treatment of pancreatic cancer. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document